tipranavir


Also found in: Medical, Wikipedia.
Related to tipranavir: Aptivus
Translations

tipranavir

n tipranavir m
References in periodicals archive ?
Atazanavir (Reyataz[R]), darunavir (Prezista[R]), fosamprenavir (Lexiva[R], Telzir[R]), indinavir (Crixivan[R]), lopinavir and ritonavir combination (Kaletra[R]), nelfinavir (Viracept[R]), saquinavir (Invirase[R], Fortovase[R]), and tipranavir (Aptivus[R]) are PIs (AIDSinfo, 2016; FDA, 2016).
Elbasvir/grazoprevir, for example, should not be used with any protease inhibitors, with nevirapine, or with efavirenz, and sofosbuvir should not be used with efavirenz, nevirapine, or tipranavir.
Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials.
atazanavir, darunavir, lopinavir, saquinavir, tipranavir, cyclosporine), strong cytochrome P450 3A (CYP3A) inducers (e.
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial.
The company offers protease inhibitors such as ritonavir, darunavir, saquinavir, amprenavir, lopinavir, atazanavir, indinavir and tipranavir.
Si se prescribe con saquinavir puede incrementar los intervalos PR o segmento QT con el riesgo de arritmia * Saquinavir * Hiperlipidemia, anormalidades de conduccion cardiaca e interacciones farmacologicas * Tipranavir * Interacciones farmacologicas con otros farmacos cardiovasculares Inhibidores de integrasa * Raltegravir * Aun no reportadas Inhibidores de entrada y de fusion * Enfuvirtida * Aun no reportadas * Maraviroc * Algunos casos de angina, insuficiencia cardiaca e infarto de miocardio.
Modification of tandem mass spectrometry method to permit simultaneous quantification of 17 anti-HIV drugs which include atazanavir and tipranavir.
Drug toxicity, HIV progression, or comorbidity of aging: Does tipranavir use increase the risk of intracranial hemorrhage?
FDA-Approved Antiretroviral Agents Nucleoside RTIs Nonnucleoside RTIs Protease inhibitors abacavir (ABC) delavirdine (DLV) atazanavir (ATV) didanosine (ddl) efavirenz (EFZ) darunavir (DRV) emtricitabine (FTC) etravirine (ETV) fosamprenavir (Fos-APV) lamivudine (3TC) nevirapine (NVP) indinavir (IDV) stavudine (d4T) lopinavir/r (LPV/r) zidovudine (ZDV) nelfinavir (NFV) ritonavir (RTV) saquinavir (SQV) tipranavir (TPV) Nucleotide RTI Integrase inhibitor Fusion inhibitor tenofovir DF (TDF) raltegravir (RAL) enfuvirtide (T-20) CCR5 antagonist maraviroc (MVC) Notes: Six fixed-dose combinations are approved by the Food and Drug Administration.
Tipranavir is associated with an increased risk of hepatotoxicity, including fatal outcomes [42,43], possibly linked to the higher ritonavir doses required.
Los hallazgos del estudio RESIST-2 durante 48 semanas de tratamiento, presentados en el Decimo Congreso Europeo de SIDA (EACS, por sus siglas en ingles) en Dublin, demuestran que el nuevo farmaco anti-VIH Tipranavir, de los laboratorios Boehringer Ingelheim, proporciona un beneficio potente y duradero a los pacientes cuyo VIH ha desarrollado resistencia a otros medicamentos anti-VIH, prolongando su expectativa de vida.